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Abstract Increase in the intracellular inositol triphosphate
(IP3) levels in Xenopus oocytes in response to expression and
activation of rat angiotensin II (Ang II) receptor AT1 was in-
hibited by co-expression of rat AT2 receptor. To identify which
region of the AT2 was involved in this inhibition, ability of three
AT2 mutants to abolish this inhibition was analyzed. Deletion of
the C-terminus of the AT2 did not abolish this inhibition. Re-
placing Ile249 in the third intracellular loop (3rd ICL) of the
AT2 with proline, corresponding amino acid in the AT1, in the
mutant M6, resulted in slightly reduced a⁄nity to [125I]Ang II
(Kd = 0.259 nM), however, did not abolish the inhibition. In
contrast, replacing eight more amino acids in the 3rd ICL of
the AT2 (at positions 241^244, 250^251 and 255^256) with that
of the AT1 in the mutant M8, not only increased the a⁄nity of
the AT2 receptor to [125I]Ang II (Kd = 0.038 nM) but also abol-
ished AT2-mediated inhibition. Interestingly, activation of the
M8 by Ang II binding also resulted in increase in the intra-
cellular IP3 levels in oocytes. These results imply that the region
of the 3rd ICL of AT2 spanning amino acids 241^256 is su⁄-
cient for the AT2-mediated inhibition of AT1-stimulated IP3
generation. Moreover, these nine mutations are also su⁄cient
to render the AT2 with the ability to activate phospholipase C.
4 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The renin-angiotensin system plays an important role in the
regulation of blood pressure and hydromineral balance
through the main e¡ector peptide angiotensin II (Ang II).
Ang II elicits its biologic actions by binding to speci¢c mem-
brane-bound receptors on target cells to activate multiple in-
tracellular signal transduction pathways [1^5]. High a⁄nity
receptors implicated in mediating the e¡ects of Ang II have
been identi¢ed in a number of peripheral tissues, such as those
of the heart, mesentric artery, aorta, adrenal cortex, liver,
uterus, bladder and pituitary. In the ovary, locally produced
Ang II is suggested to play a role in oocyte maturation [6^8].
To date, two pharmacologically di¡erent Ang II receptor sub-
types designated type 1 (AT1) and type 2 (AT2) have been
cloned and characterized [9^15]. The AT1 receptor subtype is
responsible for mediating the major physiological responses
attributable to Ang II such as vasoconstriction, secretion of
aldosterone, dipsogenic e¡ect and cell growth [2,5]. Two
highly homologous subtypes of AT1 receptor (94% amino
acid identity), termed the AT1A and AT1B respectively
were cloned from rodents [16,17]. The AT1, a 359-amino
acid protein, which belongs to the superfamily of G proteins
coupled receptors (GPCRs) activates phospholipase C (PLC)
via Gq protein and inhibits adenylyl cyclase via Gi protein
[18^20]. The third intracellular loop (3rd ICL) of the AT1
receptor is shown to interact with Gq and activate PLCL
[20^22]. Speci¢c regions on the C-terminal cytoplasmic tail
of the AT1 are involved in its coupling to Gi protein, and
activating members of the Jak/STAT family and PLCQ [19,23^
25]. The AT1 receptor is also known to activate protein kinase
C, growth-related immediate transcription factors, and several
mitogen-activated protein kinases [26^30].
The AT2 receptor gene encodes a 363-amino acid protein
and shares structural similarity (both are proteins with seven
transmembrane topology) and 34% homology at the amino
acid level with the AT1 [14,15]. The exact physiological role
of the AT2 is still emerging. Recently Vervoort et al. showed
that lack of expression of the AT2 in brain, or mutations in
the AT2 gene causes mental retardation in humans, and sug-
gested that the AT2 has an important role in brain develop-
ment and cognitive function [31]. AT2 is also known to play
important roles in the development of kidney and urinary
tract, and in the functions of ovary, uterus and pancreas
[32^35]. The AT2 seems to function as a negative regulator
of cell growth [36,37]. In many cell lines the AT2 is known to
induce apoptosis and this e¡ect is mediated by the 3rd ICL of
the AT2 [38^41]. The AT2 also seems to exert negative regu-
lation on many AT1-mediated signal pathways [42^45]. For
example, the AT1-mediated cell growth is inhibited by the
AT2 in many cell lines [46,47]. The AT2 also inhibits the
AT1-mediated inositol 1,4,5-triphosphate (IP3) production
[48,49]. Direct protein^protein interaction is one of the mech-
anisms by which the AT2 exerts its regulatory e¡ects. For
example, we have shown previously that direct protein^pro-
tein interaction exists between the domain spanning the 3rd
ICL and the C-terminal cytoplasmic tail of the AT2 receptor,
and the ATP-binding domain of ErbB3 receptor, and pro-
posed that this interaction could lead to AT2 receptor-medi-
ated inhibition of the cell growth [50]. It was shown recently
that heterodimerization of the AT2 and the AT1 receptors in
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rat pheochromocytoma PC-12 cells results in inhibition of the
AT1-mediated IP3 production by the AT2 [49]. Thus, the
antagonistic e¡ect of the AT2 on the AT1-mediated IP3 pro-
duction in these cells is caused by direct binding of the AT2 to
the AT1. Expression of the split AT2 receptors (AT21240 and
AT2241363) prevented the formation of the heterodimers and
abolished the AT2 receptor-mediated inhibition of AT1 recep-
tor-mediated IP3 production [49]. Since we have observed that
the 3rd ICL and the C-terminal cytoplasmic tail of the AT2
are needed for the direct interaction between the AT2 and the
growth-promoting ErbB3 receptor, we tested whether the
same regions are also involved in the direct interaction be-
tween the AT2 and the AT1. We used Xenopus oocyte expres-
sion system to test this idea. Initially, we analyzed whether co-
expression of the rat AT1 and AT2 receptors in Xenopus
oocytes could result in the inhibition of the AT1-mediated
IP3 production. Then we generated three AT2 mutants and
analyzed their ability to inhibit the AT1-mediated IP3 produc-
tion when co-expressed with the AT1 in these cells. This anal-
ysis helped us identify the region of the 3rd ICL of AT2
involved in the AT2-mediated inhibition of the AT1-mediated
IP3 production.
2. Materials and methods
2.1. Materials
Radiolabeled materials for sequencing and binding studies
([35S]dATP, [125I]Ang II, [125I-Sar1-Ile8]Ang II, [125I]CGP42112A)
and ‘Inositol-1,4,5-triphosphate [3H] Radioreceptor Kit’ were ob-
tained from NEN Life Science Products (Boston, MA, USA). Restric-
tion enzymes were purchased either from Boehringer Mannheim (In-
dianapolis, IN, USA) or from Promega (Madison, WI, USA).
Oligonucleotides used for sequencing and mutagenesis were purchased
from Gibco BRL Life Technologies Inc. (Gaithersburg, MD, USA).
The AT1-speci¢c antagonist losartan (DuP 753) and the AT2-speci¢c
antagonist PD123319 were obtained from Merck and Co., Inc.
(Whitehouse Station, NJ, USA) and Sigma (St. Louis, MO, USA)
respectively. The other kits used in this study were DTth DNA Poly-
merase sequencing kit (Clontech, Palo Alto, CA, USA), Quick
Change site directed mutagenesis kit (Stratagene Products, La Jolla,
CA, USA) and Riboprobe Gemini in vitro transcription system
(Promega, Madison, WI, USA). Female Xenopus laevis were obtained
from Nasco (Fort Atkinson, WI, USA).
2.2. Construction of the AT2 mutants
The C-terminal deleted AT2 receptor was generated as described
previously [51]. The construction of the AT2 mutants designated M6
and M8 were carried out by PCR-mutagenesis using ‘QuikChange1
Site Directed Mutagenesis Kit’ purchased from Stratagene Products,
La Jolla, CA, USA. A pSP64 poly(A) plasmid derivative harboring a
DNA fragment encoding the open reading frame of the AT2 receptor
described previously was used as the template [52]. To construct M6
in which the Ile249 of the AT2 was replaced with proline, the oligo-
nucleotide primers used were as follows: the forward primer was 5P-
TAT CAG AAG AAC AGA CCT ACC AGT GAC CAA GTC-3P
(+strand) and the reverse primer was 5P-GAC TG GTC ACG GGT
AGG TCT GTT CTT GTC ATA-3P (3strand). The position of the
mutation was con¢rmed by nucleotide sequencing with dideoxy chain
termination method [53]. The mutant M8 carried the following muta-
tions: T241A, N242Y, S243E, Y244I, T250R, R251N, L255F and
K256R along with I249P. This was constructed by sequentially replac-
ing the amino acids of the 3rd ICL of the AT2 with that of the AT1 at
positions 241^244, 250^251 and 255^256 along with 249 by PCR
mutagenesis. The oligonucleotide primers used to introduce the muta-
tions at positions 250^251 and 255^256 were as follows: the forward
primer was 5P-GGG AAG AAC AGA ATT AGA AAT GAC CAA
GTC TTC AGG-3P (+strand) and the reverse primer was 5P-CCT
GAA GAC TTG GTC ATT TCT AAT TCT GTT CTT CCC-3P
(3strand). The oligonucleotide primers used to introduce the muta-
tions at positions 241^244 were as follows: the forward primer was 5P-
CAT CTG CTG AAG GCC TAT GAG ATT GGG AAG AAC
AGA ATT-3P (+strand) and the reverse primer was 5P-AAT TCT
GTT CTT CCC AAT CTC ATA GGC CTT CAG CAG ATG-3P
(3strand). The positions of the mutations were con¢rmed by nucleo-
tide sequence analysis.
2.3. In vitro transcription, expression in Xenopus oocyte, ligand binding
studies and measurement of IP3 levels
To generate cRNAs corresponding to the wild type AT1, wild type
AT2, C-terminal deleted AT2, and AT2 mutants M6 and M8, in vitro
transcription was carried out. The templates used were the pSP64
poly(A) vectors carrying cDNAs corresponding to the wild type
AT2 [52], C-terminal deleted AT2 [51], M6 and M8 mutants of
AT2 (this study) and wild type AT1B (this study). The rat AT1B
was cloned in pSP64 poly(A) vector by RT-PCR amplifying the
DNA fragment corresponding to the open reading frame of the
AT1B using the forward primer 5P-ATG ACC CTT AAC TCC
TCT AC-3P (+strand) and the reverse primer 5P-TCA CTC CAC
TTC AAA AAA AGA TGC-3P (3strand) and mRNA isolated
from 17-day old rat fetus as template. In vitro transcription was
carried out using ‘Riboprobe Gemini in vitro transcription system’.
Techniques for microinjection of cRNA and ligand binding experi-
ments also were performed as described previously [52]. For IP3 mea-
surements, groups of ¢ve oocytes were used per sample as described
previously [54]. The cells were exposed to 100 nM Ang II in pre-
incubation bu¡er for 5 min. To achieve blocking of Ang II binding
with PD123319 (for the oocytes expressing AT2 and AT2 mutants) or
DuP 753 (for the oocytes expressing AT1) a 15 min pre-incubation in
the presence of appropriate antagonist was performed before the ad-
dition of Ang II. At the end of a 5 min treatment with Ang II, the
£uid was removed and the cells were subjected to £ash-freezing in
liquid nitrogen. Cells were stored at 370‡C until the assay was per-
formed according to the protocol of the ‘Inositol-1,4,5-triphosphate
[3H] Radioreceptor Kit’ purchased from NEN Life Science Products.
3. Results
3.1. AT2 receptor inhibits AT1 receptor-stimulated IP3
generation in Xenopus oocytes
The antagonistic e¡ect of the AT2 on the AT1-mediated
signal mechanisms when both receptors are co-expressed in
the same cells has been demonstrated in many situations
[42^47]. Moreover, activation of the AT2 by Ang II results
in vasodilation whereas activation of the AT1 by Ang II re-
sults in vasoconstriction [55^57]. AT1-mediated cell growth is
inhibited by the co-expression of the AT2 [46,47]. The inhibi-
tion of the AT1-mediated activation of PLC by co-expression
of the AT2 is also demonstrated previously [49]. The obser-
vation that heterodimerization of the AT2 and the AT1 re-
ceptors is responsible for the negative regulation of the AT1-
mediated signaling by the AT2 is very interesting [49]. This
observation unravels a new mechanism for cross-talk between
GPCRs, which is a direct protein^protein interaction. There-
fore, it is interesting to identify which speci¢c domain of the
AT2 is involved in this interaction with the AT1. Since inter-
action between the AT1 and the AT2 has a growth-inhibitory
e¡ect in many cell lines and we have shown previously that
the 3rd ICL and the C-terminal cytoplasmic tail of the AT2
are involved in direct protein^protein interaction between the
AT2 and the growth-promoting ErbB3 receptor, we assumed
that these two regions could also be involved in direct pro-
tein^protein interaction between the AT2 and the AT1. More-
over, we have shown previously that expression of the rat
AT1 receptor in Xenopus oocytes and activation by Ang II
results in the increase of intracellular IP3 levels [54]. We have
also shown that replacing the 3rd ICL of the AT2 with that of
the AT1 results in a chimeric receptor that is capable of in-
creasing the intracellular IP3 levels in oocytes [54]. These re-
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sults implied that Xenopus oocytes could be used as a conven-
ient expression system to test the e¡ect of co-expression of the
AT2 on the AT1-mediated increase of intracellular IP3 levels
and to identify which domain of the AT2 is involved in the
AT1^AT2 interaction.
To determine the e¡ect of co-expression and activation of
the AT2 on AT1-mediated increase of intracellular IP3 levels,
we co-injected equal amounts (25 ng) of cRNA corresponding
to the AT1 and the AT2 into the oocytes. Ligand binding
experiments using [125I]Ang II (0.5 nM) showed that both
the AT1 and the AT2 receptor subtypes were expressed in
these cells (Fig. 1). Partial blocking of the [125I]Ang II binding
was achieved when the cells were pre-incubated with the AT2-
speci¢c antagonist PD123319 (1 WM) or the AT1-speci¢c an-
tagonist losartan (1 WM) (Fig. 1). Complete blocking of the
[125I]Ang II binding to these oocytes was achieved when the
cells were pre-incubated with non-radioactive Ang II (1 WM)
(Fig. 1). Uninjected oocytes did not show any signi¢cant bind-
ing to [125I]Ang II (Fig. 1). A comparison of the intracellular
IP3 levels of the oocytes co-expressing the AT1 and the AT2
receptors to that of the oocytes expressing only the AT1 re-
ceptor is shown in Fig. 2. The activation of the AT1 receptor
Fig. 1. Ligand binding properties of the Xenopus oocytes co-expressing the wild type AT1 and AT2 receptors from rat. The speci¢c binding of
the [125I]Ang II (0.5 nM) to the oocytes co-expressing wild type AT1 and AT2 and uninjected oocytes are compared. Binding experiments were
conducted for a period of 1 h. Results are shown as relative percent of the binding of the [125I]Ang II to the oocytes co-expressing wild type
AT1 and AT2 receptor. Receptor expression was quantitated by binding studies using six to eight oocytes from at least ¢ve donors (a total of
at least 30 oocytes). Five di¡erent cRNA preparations were used for each sample. The standard errors are marked in black lines. The AT2-spe-
ci¢c antagonist PD123319 (1 WM) or the AT1-speci¢c antagonist losartan (DuP 753) (1 WM) were used for the partial blocking of the [125I]Ang
II binding. For complete blocking of the [125I]Ang II binding to these oocytes, the cells were pre-incubated with non-radioactive Ang II (1 WM).
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Fig. 2. AT2-mediated inhibition of the AT1-mediated increase in the intracellular IP3 levels of Xenopus oocytes. The IP3 levels of oocytes ex-
pressing the wild type AT1 receptor, or oocytes co-expressing di¡erent combinations of AT2 or its mutants with the AT1 (AT1 and AT2, AT1
and C-terminal deleted AT2 and AT1 and M6) are shown. The cells were exposed to 100 nM of Ang II for 5 min. When Ang II binding was
blocked with PD123319 (AT2-speci¢c ligand) or DuP 753 (AT1-speci¢c ligand), a pre-incubation in the presence of 1 WM of the appropriate
antagonist was performed before exposure to Ang II. IP3 measurements were carried out according to the protocol of the ‘Inositol-1,4,5-tri-
phosphate [3H] Radioreceptor Kit’ purchased from NEN Life Science Products. Five oocytes were used to generate one sample (about 200 Wl
of cytosol is obtained after extraction according to the procedure of RIA kit) for IP3 measurements and from each sample duplicates (100 Wl
each) were used to measure IP3 levels according to the RIA kit. Oocytes from four di¡erent frogs were used and four di¡erent cRNA prepara-
tions were used. The standard errors for each data set are marked in black lines. *Signi¢cantly di¡erent when compared with the oocytes ex-
pressing the AT1 alone (Student’s t-test, P6 0.001).
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by Ang II binding in the oocytes expressing the AT1 alone
resulted in an increase in the intracellular IP3 levels by about
seven-fold when compared to the intracellular IP3 levels of the
uninjected oocytes (Fig. 2). This increase in the intracellular
IP3 levels was abolished when these cells were pre-incubated
for 15 min in the presence of the AT1 antagonist losartan
(DuP 753) (1 WM) (Fig. 2). The intracellular IP3 levels of
the oocytes expressing the AT2 alone and exposed to Ang
II, were comparable to that of the uninjected cells which
were exposed to Ang II (Fig. 2). Co-expression of the AT2
with the AT1 resulted in abolishing the AT1-mediated in-
crease in the intracellular IP3 levels (Fig. 2). Interestingly,
pre-incubation with AT2-speci¢c antagonist PD123319 did
not reverse this e¡ect. This observation is consistent with
that found in the case of PC-12 cells co-expressing the AT1
and the AT2 receptors [49]. In those cells, the AT2-mediated
inhibition of the AT1-mediated IP3 production was indepen-
dent of AT2 activation by the Ang II. The PD123319 could
block the binding of [125I]Ang II to the AT2 receptor present
in these cells (Fig. 1). Therefore, the observation that
PD123319 could not reverse the antagonistic e¡ect of the
AT2 on the AT1-mediated IP3 production suggests that
even in Xenopus oocytes this antagonistic e¡ect of the AT2
is independent of the AT2 activation. Taken together, these
results show that the signaling induced by Ang II binding to
Xenopus oocytes co-expressing the rat AT1 and AT2 receptors
mimic the signaling induced by Ang II binding to the PC-12
cells co-expressing the AT1 and the AT2 receptors.
3.2. C-terminal cytoplasmic tail of the AT2 receptor is not
involved in the AT2 receptor- mediated inhibition of
AT1 receptor-stimulated IP3 generation
The C-terminal cytoplasmic tail of the AT2 receptor plays
an important role in the ligand binding and signaling as
shown previously [51]. This region of the AT2 was shown to
negatively regulate the AT2-mediated reduction of cyclic gua-
nosine monophosphate levels in Xenopus oocytes [51]. Delet-
ing this domain of the AT2 also inhibited the protein^protein
interaction between the AT2 and the ErbB3 receptor [51]. To
determine the role of C-terminal cytoplasmic tail of the AT2
receptor in the AT2-mediated inhibition of the AT1-mediated
IP3 production in Xenopus oocytes, we co-expressed the wild
type AT1 receptor with the C-terminal deleted AT2 and mea-
sured the levels of the intracellular IP3. As shown in Fig. 2,
the C-terminal deleted AT2 inhibited the AT1-mediated IP3
generation in a similar manner to that of the wild type AT2.
This observation implied that the C-terminal cytoplasmic tail
of the AT2 receptor is not involved in the AT2-mediated in-
hibition of the AT1-mediated IP3 production in Xenopus oo-
cytes. Inhibition with PD123319 also did not reverse the abil-
ity of the C-terminal deleted AT2 to inhibit AT1-mediated IP3
generation. This result further con¢rmed that both AT2 and
C-terminal deleted AT2 inhibited AT1-mediated IP3 genera-
tion by similar mechanism.
3.3. Mutational analysis of the 3rd ICL of the AT2 receptor
Since the C-terminal cytoplasmic tail of the AT2 did not
Fig. 3. A comparison of the amino acid sequences in the 3rd ICLs
of the wild type AT1, AT2 receptors and the AT2 mutants M6 and
M8 is shown. The numbers in the ¢gure indicate the position of the
amino acids in the AT1, AT2 and the mutants M6 and M8. The
amino acid replacements introduced into the 3rd ICL of the AT2 to
generate the AT2 mutants M6 and M8 are boxed.
Fig. 4. Ligand binding properties of the Xenopus oocytes expressing the wild type AT2 receptor and the M6 mutant (Ile249Pro). The speci¢c
binding of the [125I]Ang II (0.5 nM) and [125I]CGP42112A (0.5 nM) to the oocytes expressing wild type and mutated receptors are compared.
Binding experiments were conducted for a period of 1 h. Results are shown as relative percent of the binding of the appropriate ligand to the
oocytes expressing wild type AT2 receptor. Receptor expression was quantitated by binding studies using four to six oocytes from at least four
donors (a total of at least 16 oocytes). Four di¡erent cRNA preparations were used for each sample. The value of 100% binding of a given li-
gand to the oocytes expressing the AT2 was determined from the mean of four di¡erent data sets and the standard errors were calculated ac-
cordingly. The standard errors are marked in black lines. *Signi¢cantly di¡erent when compared with the oocytes expressing the AT2 (Student’s
t-test, P6 0.001). The extent of binding of oocytes expressing M6 mutant or the AT2 to [125I]CGP42112A was similar.
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seem to be involved in the AT2-mediated inhibition of the
AT1-mediated IP3 production in Xenopus oocytes, we then
proceeded to analyze the role of the 3rd ICL of the AT2 in
this function. We generated two mutants for this purpose. The
¢rst mutant had a proline at position 249 instead of isoleu-
cine. A comparison of the amino acids in the 3rd ICL of the
AT2 receptor and in the 3rd ICL of the AT1 is shown in Fig.
3. One striking di¡erence between these two amino acid se-
quences is the presence of a proline (Pro233) in the AT1 which
is absent in the corresponding position in the AT2. AT2 has
an isoleucine (Ile249) in this position (Fig. 3). We assumed
that introducing a proline in the 3rd ICL of the AT2 could
cause a major conformational change that would lead to al-
tering its functions. Therefore, we generated an AT2 mutant
designated M6 in which Ile249 was replaced with a proline
(Fig. 3). To determine whether this mutation in£uenced the
ligand binding properties of AT2, we microinjected equal
amounts of cRNA corresponding to wild type AT2 or M6
mutant into Xenopus oocytes. The ability of these receptors
to bind peptidic ligands [125I]Ang II and [125I]CGP42112A
(AT2-speci¢c ligand) and the non-peptidic AT2-speci¢c ligand
PD123319 was evaluated by binding assays. As shown in Fig.
4, the oocytes expressing the M6 showed slightly decreased
binding to [125I]Ang II, when compared to the binding ob-
served in the case of oocytes expressing the wild type AT2.
However, the binding of [125I]CGP42112A was comparable
for both groups of oocytes (Fig. 4). The Kd values of the
AT2 receptor and the M6 for the [125I]Ang II were found to
be 0.153 nM and 0.259 nM respectively. Similarly, for
[125I]CGP42112A, the Kd values of the AT2 receptor and
the M6 were 0.103 nM and 0.104 nM respectively. To test
the e¡ect of replacing the Ile249 by proline on the ability of
the AT2 to inhibit the AT1-mediated increase in the intra-
cellular levels of the IP3 in Xenopus oocytes, we co-expressed
both AT1 and M6 mutant in these cells. As shown in Fig. 2,
the Ile249Pro mutation did not a¡ect the ability of the AT2 to
inhibit AT1-mediated increase in the intracellular levels of the
IP3 in Xenopus oocytes. As seen in the case of AT2, inhibition
by PD123319 did not a¡ect the ability of M6 to inhibit AT1-
mediated IP3 generation. Therefore, introduction of proline at
position 249 in the AT2 did not a¡ect the mechanism by
which AT2 inhibited AT1-mediated IP3 generation.
Since converting Ile249 to proline did not alter either the
ligand binding properties or the signaling properties of the
AT2 considerably, we then introduced a series of amino
acid replacements in the 3rd ICL of the AT2. Studies have
shown that carboxy terminus (232^240) of the 3rd ICL of the
AT1 receptor is an important determinant of G protein cou-
pling [22,58]. The corresponding region of the AT2 is spanned
by the amino acids 249^256. Since we already tested the e¡ect
of the replacement of the Ile249 with proline, we continued to
make further changes in this region by replacing the amino
acids in the AT2 with that of the AT1. We introduced four
more mutations in this region and they were T250R, R251N,
L255F and K256R. The diacidic motif (Asp236^Asp237) in
the 3rd ICL of the AT1 receptor is not considered essential
for the Ang II-stimulated IP3 production, so we did not re-
place the Q253 of the AT2 with the corresponding Asp resi-
due of the AT1 [59]. Moreover, we did not alter V254 since
isoleucine in the corresponding position in the AT1 has sim-
ilar properties. However, the residues 240^244 of the AT2
were shown to be essential for the AT2-mediated apoptosis
[60]. The amino acid at position 240 in the 3rd ICL of AT2 is
a lysine. However, the corresponding amino acid in the AT1 is
also lysine, Lys223. Therefore, we replaced the amino acids
241^244 of the AT2 with the corresponding amino acids of
the AT1. The mutations introduced in this region were
T241A, N242Y, S243E and Y244I. The mutant that carried
all the nine mutations was designated M8 (Fig. 3). The bind-
ing a⁄nity of this mutant was studied in the similar manner
Fig. 5. Ligand binding properties of the Xenopus oocytes expressing the wild type AT2 receptor and the M8 mutant. The speci¢c binding of
the [125I]Ang II (0.5 nM), [125I]CGP42112A (0.5 nM), and [125I-Sar1-Ile8]Ang II (0.5 nM) to the oocytes expressing wild type and mutated re-
ceptors are compared. Binding experiments were conducted using methods similar to those described in Figs. 1 and 4. Receptor expression was
quantitated by binding studies using ¢ve oocytes from at least three donors (a total of at least 15 oocytes). Three di¡erent cRNA preparations
were used for each sample. The value for 100% binding of a given ligand to the oocytes expressing the AT2 was determined from the mean of
three di¡erent data sets and the standard errors were calculated accordingly. The standard errors are marked in black lines. *Signi¢cantly dif-
ferent when compared with the oocytes expressing the AT2 (Student’s t-test, P6 0.001). The extent of binding of [125I-Sar1-Ile8]Ang II to the
oocytes expressing AT2 or M8 was similar.
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as described for Ile249Pro mutant. Oocytes expressing the
mutant M8 demonstrated increased a⁄nity to both [125I]Ang
II and [125I]CGP42112A as shown in Fig. 5. The Kd values of
the AT2 receptor and the M8 for the [125I]Ang II were found
to be 0.153 nM and 0.038 nM respectively. Similarly, for
[125I]CGP42112A Kd values of the AT2 receptor and the M8
were calculated to be 0.103 nM and 0.068 nM respectively.
Thus, the e¡ect caused by the Ile249Pro mutation on the wild
type AT2 (a small reduction in the a⁄nity to [125I]Ang II) was
not seen when the same mutation was introduced in the pres-
ence of other mutations.
We also measured the intracellular IP3 levels of the oocytes
co-expressing the AT1 receptor and the M8. Interestingly, co-
expression of the M8 and activation by Ang II did not inhibit
the intracellular IP3 generated by Ang II-stimulated AT1 re-
ceptor (Fig. 6). Moreover, both losartan (DuP 753) and the
AT2-speci¢c antagonist PD123319 were able to reduce par-
tially the IP3 levels of oocytes co-expressing the AT1 and M8
and exposed to Ang II. Therefore, the M8 responded to the
inhibition by the AT2-speci¢c antagonist PD123319. Overall,
these observations indicated that the region of the 3rd ICL of
AT2 spanning the amino acids 241^256 is essential for the
AT2-mediated inhibition of the AT1-mediated increase in in-
tracellular IP3 levels in Xenopus oocytes.
However, these observations regarding the ligand binding
and signaling properties of the M8 raised some interesting
questions. Previously we had shown that a chimeric receptor,
in which the entire 3rd ICL of the AT2 was replaced with the
3rd ICL of the AT1, did not bind either [125I]CGP42112A or
[125I-Sar1-Ile8]Ang II with high a⁄nity [54]. This chimeric re-
ceptor carried 22 continuous amino acid replacements where
the AT2 speci¢c amino acids were replaced with that of the
AT1. The AT2 mutant M8 carried only nine of these 22 ami-
no acids replacements. Interestingly, this receptor did not
loose a⁄nity to [125I]CGP42112A as the chimeric receptor,
instead, showed increased a⁄nity when compared to that of
the AT2 (Fig. 5). Therefore, the question was whether the M8
could also bind [125I-Sar1-Ile8]Ang II with high a⁄nity like the
AT2. To explore whether the M8 di¡ered from the chimeric
receptor in its ability to bind [125I-Sar1-Ile8]Ang II, we per-
formed ligand binding experiments on oocytes expressing the
M8 using [125I-Sar1-Ile8]Ang II. As shown in Fig. 5, our re-
sults showed that the oocytes expressing the M8 could bind
the [125I-Sar1-Ile8]Ang II with high a⁄nity. The Kd values of
the AT2 receptor and the M8 for [125I-Sar1-Ile8]Ang II were
calculated to be 0.172 nM and 0.170 nM respectively. Thus,
the ligand binding properties of the chimeric receptor and the
AT2 mutant M8 were not similar. The AT2 mutant M8
seemed to retain the ability to bind all the three peptidic li-
gands ([125I] Ang II, [125I]CGP42112A or [125I-Sar1-Ile8]Ang
II) with high a⁄nity.
The second interesting question was how the AT2 antago-
nist PD123319 inhibited the IP3 generation of oocytes co-ex-
pressing the M8 and the AT1. Since the mutations in the M8
abolished the AT2-mediated inhibition of the AT1-mediated
IP3 generation, the observation that the overall IP3 generation
in oocytes co-expressing the M8 and the AT1 was partially
reduced in response to PD123319, was surprising. However, in
creating M8, what we have actually done is to mimic the
region of the AT2 spanning the amino acids 241^256 to the
Fig. 6. Co-expression of the M8 mutant did not inhibit the AT1-mediated increase in intracellular IP3 levels of Xenopus oocytes. The IP3 levels
of the oocytes solely expressing the wild type AT1 receptor are compared to that of the oocytes co-expressing the AT1 and AT2, or AT1 and
M8 mutant. Exposure of each group of oocytes to Ang II or AT1-speci¢c and AT2-speci¢c antagonists was carried as described for Fig. 2. IP3
measurements were carried out according to the protocol of the ‘Inositol-1,4,5-triphosphate [3H] Radioreceptor Kit’ purchased from NEN Life
Science Products and the techniques used were similar to those described for Fig. 2. Oocytes from three di¡erent frogs were used and three dif-
ferent cRNA preparations were used. The value for the IP3 levels of oocytes expressing the AT1 and exposed to Ang II from three di¡erent
data sets were compared, and the mean was taken as the 100%. The standard errors were calculated accordingly. The standard errors for each
data set are marked in black lines. *Signi¢cantly di¡erent when compared with the oocytes expressing the AT1 alone (Student’s t-test,
P6 0.001). However, P is 0.4353 for the di¡erences observed between the IP3 levels of oocytes expressing wild type AT1 versus the oocytes ex-
pressing both wild type AT1 and M8 mutant and exposed to Ang II. #Signi¢cantly di¡erent when compared with the oocytes co-expressing the
AT1 and the M8 and exposed to Ang II (Student’s t-test, P6 0.001).
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corresponding region of the AT1. Since many amino acids in
this region of the AT1 are implicated in its interaction with
the Gq and consequent activation of PLC [22], it was possible
that the M8 that mimics the AT1 in this region could also
have acquired the ability to activate Gq and subsequently
activate PLC. Indeed, we have seen that the chimeric receptor
that carried the 3rd ICL of the AT1 in place of the 3rd ICL of
the AT2 was capable of activating PLC [54]. Therefore, we
tested whether the M8 has acquired the ability to activate
PLC, like the chimeric receptor. Exposure of the oocytes ex-
pressing the M8 to Ang II (100 nM) resulted in increased
levels of the intracellular IP3, and this increase corresponded
to 98% of the intracellular IP3 levels of the oocytes expressing
the AT1 receptor. This M8-mediated elevation of intracellular
IP3 levels in Xenopus oocytes was inhibited when the oocytes
were pre-exposed to the AT2-antagonist PD123319 (1 WM).
Taken together these results suggested that the M8 is a mu-
tant that retains the ligand binding properties of the AT2, but
possesses at least one of the signaling properties of the AT1,
namely its ability to activate PLC. Since the M8 carries only
nine of the amino acid substitutions found in the chimeric
receptor, these results also showed that these substitutions
are su⁄cient to render the AT2 receptor with the ability to
activate PLC. Moreover, since these nine amino acid substi-
tutions did not abolish the ability of the M8 to bind
[125I]CGP42112A or [125I-Sar1-Ile8]Ang II, it is possible that
the remaining 13 amino acid substitutions made in the AT2 to
construct the chimeric receptor may have contributed to its
inability to bind the above two ligands. The ability of
PD123319 to inhibit the elevation of intracellular IP3 levels
in Xenopus oocytes co-expressing the AT1 and M8 could also
be due to the fact that the M8 was capable of activating PLC
on its own. It should be noted that we did not see a signi¢cant
increase in the overall IP3 levels of the oocytes co-expressing
the AT1 and the M8 as compared to the oocytes expressing
AT1 alone (Fig. 6). If both the AT1 and the M8 were activat-
ing the same Gq proteins or same PLC molecules, either of
these molecules could act as rate-limiting factors in the overall
IP3 generation. Therefore, although both the AT1 and the M8
could activate PLC and elevate IP3 levels, the overall increase
in the IP3 levels would depend upon the number of Gq pro-
teins and PLC molecules that were available for activation by
the M8 or the AT1 in Xenopus oocytes. Since, in oocytes co-
expressing both the AT1 and the M8, both receptors would
contribute to the activation of PLC, inhibiting the action of
one receptor could result in partial inhibition of PLC activa-
tion. This could be the reason why the AT2 antagonist
PD123319 was able to exert partial inhibition of the elevation
of intracellular IP3 levels in oocytes co-expressing both the
M8 and the AT1.
In summary, the antagonistic e¡ect of the rat AT2 expres-
sion on the PLC activation and concomitant IP3 generation
by rat AT1 receptor could be observed in Xenopus oocyte
expression system. The observation that the antagonistic e¡ect
of the AT2 on the AT1-mediated signaling is ligand indepen-
dent, further supports the idea that the nature of interaction
between the AT1 and the AT2 in Xenopus oocytes is compa-
rable to that seen in the PC-12 cells. Studies on the PC-12 cells
have established that heterodimerization between the AT1 and
the AT2 is involved in the antagonistic e¡ect of the AT2 on
the AT1 [49]. However, the speci¢c domain of the AT2 that is
needed for this interaction was not identi¢ed. Since the AT1
has to couple to Gq protein for PLC activation and the region
of the AT1 needed for coupling to Gq protein is its 3rd ICL
[18^22], any interaction between the AT1 and the AT2 that
would result in inhibition of the ability of the AT1 to activate
Gq (and thereby PLC) must occur in the cytoplasmic regions
of the AT2. Since the region of the AT2 that was needed for
its direct interaction with the ATP binding domain of the
ErbB3 receptor (which also is cytoplasmic region of the
ErbB3) included the C-terminal cytoplasmic tail and the 3rd
ICL of the AT2 [50], we hypothesized that these regions could
also be involved in the interaction between the AT2 and the
AT1. Our results show that the C-terminal cytoplasmic tail of
the AT2 does not play a signi¢cant role in this AT1^AT2
interaction. A single mutation, Ile249Pro in the 3rd ICL
was also not enough to hamper the AT1^AT2 interaction
that would abolish the ability of the AT1 to activate PLC.
Therefore, we introduced eight more selective mutations based
on what is known regarding the involvement of the amino
acids in the 3rd ICLs of the AT1 and the AT2 in their func-
tions from previous mutagenesis studies [58^60]. All the mu-
tations were replacements of the AT2 speci¢c amino acids by
corresponding AT1 speci¢c amino acids. This resulted in in-
creasing the a⁄nity of the mutant receptor, M8, to its peptidic
ligands, suggesting that the 3rd ICL of the AT2 has an im-
portant role in determining its a⁄nity to its ligands. More-
over, the slight decrease in a⁄nity to [125I]Ang II observed in
the case of M6 that carries the single mutation, Ile249Pro was
masked when eight more selective mutations were introduced
to make the M8. Our results also show that these nine muta-
tions are su⁄cient to render the AT2 receptor with the ability
to activate PLC in Xenopus oocytes. Thus, the M8 seems to be
a very interesting mutant that retains the ligand binding prop-
erties of the AT2, but has acquired at least one signaling
property of the AT1, the ability to activate PLC. Moreover,
these same mutations are also su⁄cient to abolish the AT2-
mediated inhibition of the AT1-mediated IP3 production.
Since it is established that the 3rd ICL of the rat AT1 is
involved in the activation of Gq that leads to the activation
of PLC [21,22], it is possible that the interaction to abolish the
AT2-mediated inhibition of the AT1-mediated IP3 production
could occur between the 3rd ICLs of both receptors. Finally,
our results show that the region of the 3rd ICL of the AT2
that is spanned by the amino acids 241^256 is speci¢cally
involved in this AT1^AT2 interaction.
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